EFS and OS in patients with high BCL2/MYC coexpression by treatment arm. Overall EFS (A) and OS (B) in patients with high BCL2/MYC coexpression by RNA-seq in the placebo plus R-CHOP and ibrutinib plus R-CHOP arms.